康乃德生物医药公布静脉注射雷德米基巴治疗哮喘或慢阻肺患者一期研究积极顶线数据

投资观察
Mar 30

康乃德生物医药控股有限公司宣布,其静脉注射雷德米基巴在哮喘或慢性阻塞性肺病患者中开展的一期研究获得积极顶线结果。

研究数据显示,通过静脉推注给予300毫克雷德米基巴后,哮喘和慢阻肺患者的第一秒用力呼气容积迅速改善,增幅达到或超过200毫升。该药物展现出良好的耐受性,研究中未出现严重或重度不良事件。

目前,公司正在推进第二阶段SEABREEZE STAT研究的患者招募工作,该项研究的顶线数据预计将于2026年中期公布。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10